Master's Thesis

Assaying Dry Powder Formulation Permeability Using Nasal Mucosa Air-Liquid Interface with RPMI 2650 cells

Rita Martins Alexandre — 2025

Key information

Authors:

Rita Martins Alexandre (Rita Martins Alexandre)

Supervisors:

Tiago Paulo Gonçalves Pinheiro Fernandes (Tiago Paulo Gonçalves Fernandes); Alexandre José Soares dos Santos Ribeiro

Published in

July 8, 2025

Abstract

The intranasal route has emerged as a non-invasive and efficient alternative for both brain-targeted, systemic or local drug delivery, due to its ability to bypass the hepatic first-pass effect and either directly reach the brain or enable rapid absorption through the highly vascularized nasal mucosa. However, the lack of reliable in vitro models to assess the permeability of dry powder formulations remains a significant limitation in early drug development. This study proposes and validates a robust in vitro method for evaluating the permeability of inhaled dry powder drugs using a nasal air-liquid interface (ALI) model composed of RPMI 2650 cells. The epithelial integrity of the ALI model was characterized through critical quality attributes (CQAs) including transepithelial electrical resistance (TEER), mucus quantification, and immunocytochemistry of tight junction proteins. Piroxicam (PRX), a non-steroidal anti-inflammatory drug, was selected as a model compound and tested both as active pharmaceutical ingredient (API) and in a hydroxypropylmethyl cellulose (HPMC)-based dry powder formulation. The quantities tested were validated through cell viability analysis. Permeability studies demonstrated that the ALI model provides repeatable and biologically relevant results, revealing measurable fluxes of PRX under varying experimental conditions. Furthermore, the use of a nasal device to deliver the dry powder ensured consistent deposition without compromising epithelial barrier integrity. The proposed method offers a predictive and physiologically relevant approach for evaluating nasal drug permeability, thereby accelerating formulation and nasal administration development while reducing the reliance on animal testing.

Publication details

Authors in the community:

Supervisors of this institution:

Fields of Science and Technology (FOS)

industrial-biotechnology - Industrial Biotechnology

Publication language (ISO code)

eng - English

Rights type:

Embargoed access

Date available:

July 8, 2027

Institution name

Instituto Superior Técnico